Baxevanos Panagiotis

• Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy., Mountzios G, de Toma A, Economopoulou P, Friedlaender A, Banini M, Lo Russo G, Baxevanos P, Roila F, Banna GL, Christopoulou A, Jimenez B, Collazo-Lorduy A, Linardou H, Calles A, Galetta D, Addeo A, Camerini A, Pizzutilo P, Kosmidis P, Garassino MC, Proto C, Signorelli D, Metro G., Clin Lung Cancer, 03/21, 22, 2, e180-e192, 10.1016/j.cllc.2020.09.017, 33162330
• Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%., Metro G, Banna GL, Signorelli D, Gili A, Galetta D, Galli G, Economopoulou P, Roila F, Friedlaender A, Camerini A, Christopoulou A, Cantale O, De Toma A, Pizzutilo P, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Giannarelli D, Mountzios G, Addeo A., J Immunother, 11/20, 43, 9, 299-306, 10.1097/CJI.0000000000000340, 32991393
• Impact of Performance Status on Non Small Cell Lung Cancer Patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab., Friedlaender A, Metro G, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Mountzios G, Garassino MC, Addeo A., Acta Oncol, 09/20, 59, 9, 1058-1063, 10.1080/0284186X.2020.1781249, 32762415
• Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort., Economopoulou P, Roila F, Banna G, De Toma A, Rey Cobo J, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Garassino MC, Mountzios G., J Thorac Dis, 12/19, 11, 12, 4972-4981, 10.21037/jtd.2019.12.23, 32030213, PMC6988053
• PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer., Tsoukalas N, Kiakou M, Tsapakidis K, Tolia M, Aravantinou-Fatorou E, Baxevanos P, Kyrgias G, Theocharis S., J BUON, 05/19, 24, 3, 883-888, 31424637
• Advances On Systemic Treatment for Lung Neuroendocrine Neoplasms, Tsoukalas N, Baxevanos P, Aravantinou-Fatorou E, Tolia M, Galanopoulos M, Tsapakidis K, Kyrgias G, Toumpanakis C, Kaltsas G., Ann Transl Med, 04/18, 6, 8, 146, 10.21037/atm.2018.04.03, 29862235, PMC5952021
• Advanced small cell lung cancer (SCLC): new challenges and new expectations., Tsoukalas N, Aravantinou-Fatorou E, Baxevanos P, Tolia M, Tsapakidis K, Galanopoulos M, Liontos M, Kyrgias G., Ann Transl Med, 04/18, 6, 8, 145, 10.21037/atm.2018.03.31, 29862234, PMC5952028
• Novel Chemotherapy Regimens for Advanced Lung Cancer: Have we Reached a Plateau?, Baxevanos P, Mountzios G., Ann Transl Med, 04/18, 6, 8, 139, 10.21037/atm.2018.04.04, 29862228
• Carcinoembryonic antigen and carbohydrate antigen 19-9 serum levels in non-small cell lung cancer., Tsoukalas N, Kostakis ID, Giaginis C, Tolia M, Galanopoulos M, Kiakou M, Aravantinou-Fatorou E, Tsapakidis K, Baxevanos P, Litos I, Tzouda V, Tzovaras A, Kyrgias G, Tsiambas E, Theocharis S., J BUON, 11/17, 22, 6, 1390-1394, 29332328
• Optimizing EGFR Targeted Therapy in Pancreatic Cancer., Baxevanos P and Fountzilas C., Austin Pancreat Disord, 2017, 1, 1, 1005

• Poor performance status and front-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC) patients with PD-L1>50%., 2020 ASCO Annual Meeting, 2020, Journal of Clinical Oncology, 38, 15_suppl, e21651-e21651, 10.1200/JCO.2020.38.15_suppl.e21651
• 1518P Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest., ESMO 2019, Barcelona, Spain, 09/27 - 10/01/19, Annals of Oncology, https://doi.org/10.1093/annonc/mdz260.040
• Prognostic role white blood cell levels in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy., ESMO 2019, Barcelona, Spain, 09/27 - 10/01/19, Annals of Oncology, https://doi.org/10.1093/ANNONC/MDZ155.291
• Primary breast carcinosarcoma., International Gynecologic Cancer Society (IGCS) 2019, 09/19, International Journal of Gynecological Cancer, https://doi.org/10.1136/IJGC-2019-IGCS.368
• Post-Progression Outcomes After Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: Real World Data from a European Cohort., IASLC 20th World Conference on Lung Cancer, Barcelona, Spain, 09/07 - 09/10/19, Journal of Thoracic Oncology, https://doi.org/10.1016/J.JTHO.2019.08.1235
• Clinical significance of RCAS1 and CD3 expression in non-small cell lung cancers in immunotherapy era., ESMO 2018, Munich, Germany, 10/19 - 10/23/18, Annals of Oncology, https://doi.org/10.1093/annonc/mdy269.174
• Clinical Impact of Systematic Inflammation and Histologic Grade in Non Small Cell Lung Carcinoma (NSCLC)., IASLC 19th World Conference on Lung Cancer, Toronto, Canada, 09/23 - 09/26/18, Journal of Thoracic Oncology, https://doi.org/10.1016/j.jtho.2018.08.811
• Clinical Significance of Cannabinoid Receptor CB2 Expression in Non Small Cell Lung Cancer (NSCLC)., IASLC 19th World Conference on Lung Cancer, Toronto, Canada, 09/23 - 09/26/18, Journal of Thoracic Oncology, https://doi.org/10.1016/j.jtho.2018.08.812

40, Delivered in Greek Oncological Conferences

• State of The Art – MATCH (Multidisciplinary Approach of the Tumor of the Chest) preceptorship, Oncology Unit, 3rd Department of Internal Medicine, National and Kapodistrian University of Athens, 10/14 - 10/15/22
• ESMO Preceptorship: Adolescents and Young Adults Malignancies - Multidisciplinary management, standards of care and future perspectives., 05/11 - 05/12/18, Lugano, Switzerland

• Hellenic Society of Medical Oncology (HeSMO), 2022 - present
• European Society of Medical Oncology (ESMO), 2018 - present
• Hellenic Society of Cardiopulmonary Resuscitation, 2017 - present
• Medical Association of Athens, 2011 - present

• Running
• Basketball